Novel parathyroid hormone-based bone graft substitute, KUR-111, in treatment of tibial plateau fractures: a prospective, randomised, open-label, multicenter study

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

The treatment of closed tibial plateau fractures (TPF) is complex and carries a risk of malunion.

Parathyroid hormone (PTH) plays a key role in bone metabolism, and a PTH-peptide (PTH1 - 34) promotes bone healing.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

Everyone knew when Parathyroid Hormone (PTH 1-84) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Parathyroid Hormone (PTH 1-84) study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Tibial Fractures, Fracture Healing, Bone Substitutes, Bone Transplantation, Parathyroid Hormone, Tomography, X-Ray Computed and Ilium.

The authors tagged it with the keywords DGU Trauma Network, Extremity trauma, Interdisciplinarity, NATO treaty case, Patient Distribution and War injuries.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Parathyroid Hormone (PTH 1-84).

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (European journal of orthopaedic surgery & traumatology : orthopedie traumatologie), a journal based in France.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.